Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting

Lignende værker

• TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer
  af: Kato, Renpei, et al.
  Udgivet: (2020)
• Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
  af: Zhao, X., et al.
  Udgivet: (2017)
• Rapid progression of recurrent disease in a patient with renal cell carcinoma with vaginal metastasis
  af: Hisano, Mizuki, et al.
  Udgivet: (2020)
• Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers
  af: Bei, Di, et al.
  Udgivet: (2020)
• Appropriate preoperative membranous urethral length predicts recovery of urinary continence after robot-assisted laparoscopic prostatectomy
  af: Ikarashi, Daiki, et al.
  Udgivet: (2018)